Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.

BACKGROUND:It has been found that thiazolidinediones (TZDs) may play a protective role in animal models of Parkinson's disease (PD), while the results remain controversial whether TZDs protect against Parkinson's disease in humans. The purpose of this meta-analysis is to explore the associ...

Full description

Bibliographic Details
Main Authors: Yueli Zhu, Jiali Pu, Yanxing Chen, Baorong Zhang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0224236
_version_ 1818833725930078208
author Yueli Zhu
Jiali Pu
Yanxing Chen
Baorong Zhang
author_facet Yueli Zhu
Jiali Pu
Yanxing Chen
Baorong Zhang
author_sort Yueli Zhu
collection DOAJ
description BACKGROUND:It has been found that thiazolidinediones (TZDs) may play a protective role in animal models of Parkinson's disease (PD), while the results remain controversial whether TZDs protect against Parkinson's disease in humans. The purpose of this meta-analysis is to explore the association between TZDs use and the incidence of PD in diabetic patients. METHODS:A systematic online search was conducted to find studies published up to 31 December 2018. In our exploratory meta-analysis, studies comparing incidence of PD between TZD-treated and non-TZD-treated groups of diabetic patients were included. Data analysis was performed using a random or fixed effects model and expressed as odds ratios (OR) with 95% confidence interval (95% CI). We used the Cochrane Collaboration's Review Manager 5.3 software to analyze data. RESULTS:In total, 5 retrospective observational cohort studies were identified which met the inclusion criteria. The pooled odds ratio (OR) was 0.70 [95% CI, 0.51 to 0.96; p = 0.03] in a random-effects model, indicating a 30% lower risk of developing PD in diabetic patients treated with TZDs compared with non-TZD-treated patients. CONCLUSION:In this exploratory meta-analysis, we found that TZDs use was associated with reduced risk of PD in diabetic patients. However, this meta-analysis was not registered online although we followed a protocol designed for it. Further prospective observational studies with larger sample size and more strict inclusion criteria including controlling for diabetes complication severity index, hypoglycemic drugs combination, sex ratio, and comorbidity are needed to guide whether RCTs are warranted. And RCTs can better determine whether TZDs use could lower incidence of PD in diabetic patients.
first_indexed 2024-12-19T02:23:30Z
format Article
id doaj.art-cc0c7fa291fa4440807a66a8e1e243a3
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-19T02:23:30Z
publishDate 2019-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-cc0c7fa291fa4440807a66a8e1e243a32022-12-21T20:40:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011410e022423610.1371/journal.pone.0224236Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.Yueli ZhuJiali PuYanxing ChenBaorong ZhangBACKGROUND:It has been found that thiazolidinediones (TZDs) may play a protective role in animal models of Parkinson's disease (PD), while the results remain controversial whether TZDs protect against Parkinson's disease in humans. The purpose of this meta-analysis is to explore the association between TZDs use and the incidence of PD in diabetic patients. METHODS:A systematic online search was conducted to find studies published up to 31 December 2018. In our exploratory meta-analysis, studies comparing incidence of PD between TZD-treated and non-TZD-treated groups of diabetic patients were included. Data analysis was performed using a random or fixed effects model and expressed as odds ratios (OR) with 95% confidence interval (95% CI). We used the Cochrane Collaboration's Review Manager 5.3 software to analyze data. RESULTS:In total, 5 retrospective observational cohort studies were identified which met the inclusion criteria. The pooled odds ratio (OR) was 0.70 [95% CI, 0.51 to 0.96; p = 0.03] in a random-effects model, indicating a 30% lower risk of developing PD in diabetic patients treated with TZDs compared with non-TZD-treated patients. CONCLUSION:In this exploratory meta-analysis, we found that TZDs use was associated with reduced risk of PD in diabetic patients. However, this meta-analysis was not registered online although we followed a protocol designed for it. Further prospective observational studies with larger sample size and more strict inclusion criteria including controlling for diabetes complication severity index, hypoglycemic drugs combination, sex ratio, and comorbidity are needed to guide whether RCTs are warranted. And RCTs can better determine whether TZDs use could lower incidence of PD in diabetic patients.https://doi.org/10.1371/journal.pone.0224236
spellingShingle Yueli Zhu
Jiali Pu
Yanxing Chen
Baorong Zhang
Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
PLoS ONE
title Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
title_full Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
title_fullStr Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
title_full_unstemmed Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
title_short Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
title_sort decreased risk of parkinson s disease in diabetic patients with thiazolidinediones therapy an exploratory meta analysis
url https://doi.org/10.1371/journal.pone.0224236
work_keys_str_mv AT yuelizhu decreasedriskofparkinsonsdiseaseindiabeticpatientswiththiazolidinedionestherapyanexploratorymetaanalysis
AT jialipu decreasedriskofparkinsonsdiseaseindiabeticpatientswiththiazolidinedionestherapyanexploratorymetaanalysis
AT yanxingchen decreasedriskofparkinsonsdiseaseindiabeticpatientswiththiazolidinedionestherapyanexploratorymetaanalysis
AT baorongzhang decreasedriskofparkinsonsdiseaseindiabeticpatientswiththiazolidinedionestherapyanexploratorymetaanalysis